Acorda Therapeutics, Inc. ACOR · Stock Open Acorda Therapeutics, Inc. in new tab
Acorda Therapeutics, Inc. Analysis (ACOR)
Is Acorda Therapeutics, Inc. a good investment? Acorda Therapeutics, Inc. (ACOR) is currently trading at 0.6610 USD.
Investor FAQ
Does Acorda Therapeutics, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Acorda Therapeutics, Inc.?
Acorda Therapeutics, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
Company Profile
Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Inbrija for the treatment of OFF periods in Parkinson's disease in Europe. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops ARCUS product for the treatment of acute migrain; rHIgM22, which has completed Phase I clinical trial for the treatment of MS; and Cimaglermin alfa for heart failure patients. The company has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. Acorda Therapeutics, Inc. was incorporated in 1995 and is headquartered in Ardsley, New York.
| Split Date | Split Ratio to 1 |
|---|---|
| Jan. 4, 2021 | 0.17 |
| June 5, 2023 | 1:20 |
Community Discussion